Holen Sie sich die Stockscreener-App
14.81
12.03%
1.59
Handel nachbörslich:
14.55
-0.26
-1.76%
Schlusskurs vom Vortag:
$13.22
Offen:
$13.61
24-Stunden-Volumen:
2.46M
Relative Volume:
1.57
Marktkapitalisierung:
$2.15B
Einnahmen:
$340.81M
Nettoeinkommen (Verlust:
$-419.65M
KGV:
-5.1965
EPS:
-2.85
Netto-Cashflow:
$-402.10M
1W Leistung:
+3.21%
1M Leistung:
+2.00%
6M Leistung:
-30.50%
1J Leistung:
-35.66%
1-Tages-Spanne:
$13.37
$15.06
1-Wochen-Bereich:
$12.91
$15.06
52-Wochen-Spanne:
$10.57
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Firmenname
Denali Therapeutics Inc
Sektor
Branche
Telefon
(650) 866-8547
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Vergleichen Sie DNLI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
14.81 | 1.92B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2025-01-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-01-03 | Eingeleitet | William Blair | Outperform |
| 2024-12-16 | Hochstufung | Stifel | Hold → Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Eingeleitet | B. Riley Securities | Buy |
| 2023-01-30 | Eingeleitet | SVB Securities | Outperform |
| 2022-12-05 | Eingeleitet | Cowen | Outperform |
| 2022-11-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-02 | Eingeleitet | BofA Securities | Buy |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-01 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-05-18 | Eingeleitet | UBS | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
| 2020-02-19 | Eingeleitet | Stifel | Hold |
| 2020-01-27 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-26 | Eingeleitet | Wedbush | Neutral |
| 2019-09-13 | Eingeleitet | Nomura | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Eingeleitet | Janney | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Eingeleitet | Goldman | Neutral |
| 2018-01-02 | Eingeleitet | JP Morgan | Overweight |
| 2018-01-02 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 - Yahoo Finance
Denali Therapeutics Inc. SEC 10-Q Report - TradingView
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
FDA Fast-Tracks Denali's Breakthrough Hunter Syndrome Drug as Pipeline Expands - Stock Titan
Possible Bearish Signals With Denali Therapeutics Insiders Disposing Stock - 富途牛牛
BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Is Denali Therapeutics Inc. a good long term investmentMaster stock selection with insider knowledge - Jammu Links News
How strong is Denali Therapeutics Inc. company’s balance sheetCapitalize on momentum stocks before they peak - Jammu Links News
What are Denali Therapeutics Inc. company’s key revenue driversInvest smarter with daily market updates - Jammu Links News
What institutional investors are buying Denali Therapeutics Inc. stockFree Technical Analysis Support - Jammu Links News
What is Denali Therapeutics Inc. company’s growth strategyConsistent triple-digit returns - Jammu Links News
Is Denali Therapeutics Inc. stock overvalued or undervaluedAchieve unparalleled market performance - Jammu Links News
Does Denali Therapeutics Inc. stock perform well during market downturnsMaximize gains with expert trading strategies - Jammu Links News
How does Denali Therapeutics Inc. generate profit in a changing economyMarket-leading profit generation - Jammu Links News
What makes Denali Therapeutics Inc. stock price move sharplyCapitalize on market momentum for maximum gains - Jammu Links News
How volatile is Denali Therapeutics Inc. stock compared to the marketFree Daily Trading Room Entry - Jammu Links News
What is the risk reward ratio of investing in Denali Therapeutics Inc. stockSky-high return potential - Jammu Links News
Is Denali Therapeutics Inc. a growth stock or a value stockAccelerated financial growth - Jammu Links News
What are analysts’ price targets for Denali Therapeutics Inc. in the next 12 monthsInvest smarter with cutting-edge analytics - Jammu Links News
Is it the right time to buy Denali Therapeutics Inc. stockTransform your portfolio with high-yield stocks - Jammu Links News
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation - MSN
Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy - Insider Monkey
Price momentum metrics for Denali Therapeutics Inc. explainedStock Portfolio Allocation Guidance for Volatile Markets - metal.it
11 Best Future Stocks to Buy Now - Insider Monkey
Biogen’s BIIB122 Study: A New Hope for LRRK2-Associated Parkinson’s Disease - TipRanks
Can Denali Therapeutics Inc. Rally Enough to Break EvenReal Profit Trade Plan Suggestions Shared Widely - metal.it
Volume Surge May Signal Institutional Interest in Denali Therapeutics Inc.Trade Setups With Clear Risk Limits Highlighted - metal.it
What are the technical indicators suggesting about Denali Therapeutics Inc.Real Time Guidance For 2025 - jammulinksnews.com
Published on: 2025-07-28 03:16:35 - Jammu Links News
Published on: 2025-07-27 16:21:55 - Jammu Links News
BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target - MSN
Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):